Clik here to view.
路胜生物与A*STAR分享研究数据，显示SAFER™ Sample唾液采样盒可灭活采集的COVID-19病毒
新加坡 (美国商业资讯)–分子诊断公司路胜生物(Lucence)和新加坡科技研究局(A*STAR)今天宣布的研究结果表明，路胜生物的SAFER Sample唾液采样盒中使用的试剂可在采样后45秒内灭活SARS-CoV-2。该专利试剂还可在室温下稳定病毒RNA长达一周。这些特性加在一起，可通过唾液实现无障碍、无创、安全的采样，这对于在全球推广具有成本效益的检测至关重要。路胜生物的SAFER...
View ArticleClik here to view.
ルーセンスとA*STARがCOVID-19向けSAFER™ Sample唾液採取キットが採取ウイルスを不活化することを示す研究データを発表
シンガポール （ビジネスワイヤ） — 分子診断企業のルーセンスとシンガポール科学技術研究庁（A*STAR）は本日、ルーセンスの唾液採取キットSAFER...
View ArticleClik here to view.
PHCホールディングス株式会社：エプレディアによるLunaphoreとのLabSat Researchの独占販売にかかる契約締結について
東京 （ビジネスワイヤ） — PHCホールディングス株式会社（本社：東京都港区）の100%子会社で、精緻ながん診断・組織診断領域におけるグローバルリーダーであるEpredia（本社：米国 ニューハンプシャー州ポーツマス、以下「エプレディア」）と、がん研究における革新的な次世代機器を開発するスイスのライフサイエンス企業Lunaphore Technologies SA（本社：スイス...
View ArticleClik here to view.
Terns Pharmaceuticals Initiates the LIFT Study, a Phase 2a Clinical Trial of...
FOSTER CITY, Calif. & SHANGHAI Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat liver disease and cancer, today...
View ArticleClik here to view.
Terns Pharmaceuticals、NASH治療に向けたTERN-101の第2a相臨床試験LIFTを開始
米カリフォルニア州フォスターシティ & 上海 （ビジネスワイヤ） — 肝疾患とがんの革新的治療薬の創薬と開発に傾注する世界的バイオ製薬会社のTerns Pharmaceuticals,...
View ArticleClik here to view.
Merck’s KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment...
KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the National Medical Products...
View ArticleClik here to view.
Nanox Enters Asia Pacific: Signs Strategic Agreement With Golden Vine...
NEVE ILAN, Israel & TAIPEI, Taiwan NANO-X IMAGING LTD (www.nanox.vision) (“Nanox” or the “Company”), an innovative medical imaging technology company, announces it has signed an exclusive...
View ArticleClik here to view.
EpimAb Biotherapeutics Presents Preclinical Data Characterizing EMB-01 at...
SHANGHAI EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, today presented preclinical data at the 2020 American Association for...
View ArticleClik here to view.
次世代のバイオテクノロジーパイプラインを創出すべくシリーズB資金調達で2300万カナダドルを確保
トロント （ビジネスワイヤ） — ネオバイオテクノロジー企業のサイクリカは本日、2300万カナダドルのシリーズB資金調達を完了したと発表しました。本ラウンドはドライブ・キャピタルが主導し、Chiesi Farmaceutici、グリーンスカイ・キャピタル、サイクリカ経営陣のメンバーが参加しました。...
View ArticleClik here to view.
Cyclica筹集2300万加元B轮融资，用于研制未来的生物技术产品管线
多伦多 (美国商业资讯)–新兴生物技术公司Cyclica今天宣布完成2300万加元B轮融资。此轮融资由Drive Capital领投，Chiesi Farmaceutici、GreenSky Capital和Cyclica管理团队成员参投。...
View ArticleClik here to view.
Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative...
TOKYO, MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the first patient with triple negative breast cancer (TNBC) has been dosed in the...
View ArticleClik here to view.
EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan...
TOKYO & MUNICH Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA)...
View ArticleClik here to view.
Samyang Biopharm USA Announces Establishment of “Samyang CRS Award in Honor...
CAMBRIDGE, Mass. & SEOUL, South Korea Samyang Biopharm USA, Inc. (https://us.Samyangbiopharm.com) a global biotech subsidiary of the Samyang Pharmaceuticals Corp....
View ArticleClik here to view.
Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical Announce FDA...
PLEASANTON, Calif. & PRINCETON, N.J. & TOKYO Astex Pharmaceuticals, Inc.; Taiho Oncology, Inc.; and Otsuka Pharmaceutical Co., Ltd. today announce that the U.S. Food and Drug Administration...
View ArticleClik here to view.
With Second Mevion Proton System Installed at Siteman Cancer Center,...
LITTLETON, Mass. Mevion Medical Systems announced today that patient treatment has commenced on the MEVION S250i Proton Therapy System® at the S. Lee Kling Proton Therapy Center at Siteman Cancer...
View ArticleClik here to view.
Takeda and the New York Academy of Sciences Announce 2020 Innovators in...
NEW YORK & OSAKA, Japan Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) and the New York Academy of Sciences announced today the Winners of the third annual Innovators in...
View ArticleClik here to view.
RefleXion and Telix Pharmaceuticals Announce Strategic Collaboration for...
HAYWARD, Calif. & MELBOURNE, Australia RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, and...
View ArticleClik here to view.
武田和纽约科学院公布2020年科学创新者奖获得者
纽约和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（“武田”）和纽约科学院(New York Academy of Sciences)今天公布了第三届年度科学创新者奖(Innovators in Science...
View ArticleClik here to view.
Harbour BioMed Raises $102.8M in Series C Financing to Accelerate Development...
Cambridge, MA, Rotterdam, NL, Suzhou CN Harbour BioMed (HBM) today announced completion of its Series C financing of $102.8 Million to accelerate development of its growing portfolio of next...
View ArticleClik here to view.
JS InnoPharm Announces First Patient Dosed with JSI-1187, a Selective ERK...
CHICAGO & SHANGHAI JS InnoPharm Ltd today announced the enrollment of the first patient in a Phase 1, open-label, monotherapy dose-escalation and expansion study of JSI-1187, the company’s lead...
View Article